Hugues Bultot

TLDR

Hugues Bultot is co-founder and CEO of Univercells, a Belgian biotech group that has developed compact, high-intensity biomanufacturing platforms for vaccines, viral vectors, and biologics.

Overview

Hugues has over 15 years as a serial entrepreneur in life sciences and biotechnology. Before Univercells he served as CEO of MaSTherCell (acquired by Catalent in 2020), Artelis, and Kitozyme. He holds a Master in Law from UCLouvain, an Executive MBA from Solvay Business School, a tax management degree from ICHEC, and an innovation certification from MIT Sloan.

Univercells was founded in 2013 with the mission of making biologics accessible globally. The company's NevoLine platform radically reduces the footprint of biomanufacturing facilities from up to 10,000m2 down to 1,500m2. KKR invested EUR 50 million through the Gamma funding platform, and the European Investment Bank provided EUR 30 million for COVID-19-related projects.